Iol Chemicals & Pharmaceuticals Ltd. · NSE:IOLCP
Iol Chemicals & Pharmaceuticals — Investor Presentation (August 2021)
24 slides from Iol Chemicals & Pharmaceuticals's investor presentation, August 2021
Slide 1: IOL Chemicals and Pharmaceuticals Limited Investor Presentation August 2021
IOL Chemicals and Pharmaceuticals Limited Investor Presentation August 2021
Slide 2: Disclaimer
Disclaimer This information may contain certain forward-looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views ex
Slide 3: About IOL Chemicals and Pharmaceuticals Limited
About IOL Chemicals and Pharmaceuticals Limited Incorporated in 1986, IOLCP is one of the leading Pharmaceuticals company and is a significant player in the field of specialty chemicals with world class facilities Catering to the top-tier players across diverse important industries like pharmaceutic
Slide 4: Key Highlights
Key Highlights Team size of 2,000+ Largest producer of Largest producer of Ethyl 2nd Largest producer of Over 20 products are employees Ibuprofen and the only Acetate at Single Location Iso Butyl Benzene (IBB) commercialised with 8 company worldwide being in India with ~30% Global share products in
Slide 5: Professional Management Team
Professional Management Team Mr. Varinder is an industrialist and has wide and rich Mr. Vikas is academically equipped with the experience of more than 35 years in the chemical & knowledge and possesses organizational capacity. He fertilizer industry and along with a comprehensive has worked in stra
Slide 6: Experienced Independent Directors
Experienced Independent Directors Rajender Mohan Malla Dr. Sandhya Mehta Harpal Singh (Chairman and Independent (Independent Director) (Independent Director) Director) • Mr. Rajender has very distinguished career • Dr. Sandhya is working as the principal of • Mr. Harpal has had over 35 year's of fou
Slide 7: Our Journey
Our Journey Unit-08 & Unit-10* Unit-06 for Pantoprazole Unit-03 for new for Multi Products 2020 (Dedicated) 2018 product facility 2012 Unit-07 Metformin Unit-04 Metformin Unit-02 for Ibuprofen 2021 (Dedicated) 2019 (Dedicated) 2016 (Dedicated) Unit-05 Clopidogrel & Fenofibrate Unit-01 Ibuprofen (Ded
Slide 8: Certifications and Accreditations
Certifications and Accreditations Approved USFDA Ibuprofen EUGMP Certification in Certificate of Suitability Certificate of Suitability facility since 2015, 2013, 2017 & from EDQM for from EDQM for recertified in 2019 Recertification in 2020 IBUPROFEN, CEP No. 316- LAMOTRIGINE, CEP No. 2008 066-2013
Slide 9: Product Segmentation
Product Segmentation 9
Slide 10: Business Segment – Pharmaceuticals
Business Segment – Pharmaceuticals IOLCP is the largest producer of Ibuprofen with ~35% Global share and the only company worldwide being backward integrated for all Intermediates and Key Starting Material of Ibuprofen Among the largest Added more than 7 new Product portfolio that producer of Metfor
Slide 11: Pharmaceuticals Product Portfolio – Commercialized & Pipeline
Pharmaceuticals Product Portfolio – Commercialized & Pipeline API - Commercialized API - Pipeline Ibuprofen Fexofenadine Ibuprofen Lysinate Ibuprofen Sodium Quetiapine Fumarate Dex-Ibuprofen Dextromethorphan Metformin HCL Clopidogrel Bisulphate (Form II) Apixaban Pantoprazole Sodium Fenofibrate (Mic
Slide 12: Business Segment – Specialty Chemicals
Business Segment – Specialty Chemicals IOLCP first commenced manufacturing Ethyl Acetate in 1996, with a starting capacity of 3000 tonnes per annum. Today, the Company has grown this business to become the largest single location plant in India, with a production capacity of 100,000 tonnes per annum
Slide 13: Product wise Segmentation – Quarterly
Product wise Segmentation – Quarterly Q1 FY22 Q4 FY21 Q1 FY21 270.0 153.9 58.0% 169.3 29.3% 36.3% 307.5 243.9 58.7% 52.3% 62.8 150.2 12.0% 53.4 32.2% 45.7 11.4% 9.8% Other Pharma Chemicals Ibuprofen Products 13 All figures in INR crs unless stated
Slide 14: Manufacturing Facility spread across over 100 acres with GMP approved guidelines
Manufacturing Facility spread across over 100 acres with GMP approved guidelines API manufactured in batch manner and Facility is coupled with ISO class-8 HVAC intermediates & Specialty chemicals in Dedicated blocks involved in manufacturing system, PSA Nitrogen & Purified water along continuous pro
Slide 15: Our Core Sustainability Pillars
Our Core Sustainability Pillars Solar Lights donated by IOLCP • Strive to minimize the adverse impact on • Construction and renovation of school locations, environment, health and Safety by upgrading provided technical equipment for smart education technology, optimum utilization of resources and •
Slide 16: Financial Overview
Financial Overview 16
Slide 17: Key Financial Summary
Key Financial Summary Financial Summary Q1FY22 Q4FY21 Q1FY21 (INR Cr) Total Income 524 467 466 Gross Profit 189 189 218 EBITDA 116 117 158 PAT 67 75 128 17 All Profits and Total Income include Other Income
Slide 18: 5 years Financial Performance - Annually
5 years Financial Performance - Annually Revenues & Margins* – Annual Margin* Expansion – Over the Years 2,000 1,910 1,991 50% 50% Gross % 1,800 1,696 45% 45% 45% 45% 12% 1,600 44% 40% 40% EBITDA % 1,400 33% 38% 31% 31% 35% 35% 33% 30% 31% 1,200 25% 30% 30% 16% 990 22% PAT % 22% 1,000 25% 25% 19% 80
Slide 19: Quarterly Financial Performance
Quarterly Financial Performance Revenues & Margins* 800 46.7% 50% 700 40.5% 36.1% 40% 600 33.9% 524.2 500 465.9 466.6 30% 400 25.2% 27.4% 22.1% 300 20% 200 16.1% 12.8% 10% 100 - 0% Q1FY21 Q4FY21 Q1FY22 Total Income Gross Profits % EBITDA % PAT % Segmental EBIT % 45% 30% 44.1% 40% 25% 35% 29.7% 20% 3
Slide 20: Geographical Segmental Breakup – Annual & Quarterly
Geographical Segmental Breakup – Annual & Quarterly In INR crs 500 1,600 450 435 1,400 1,354 1,250 400 1,200 1,038 350 318 300 1,000 300 800 250 633 647 644 613 200 600 160 484 143 150 400 350 227 100 83 200 50 - 0 FY17 FY18 FY19 FY20 FY21* Jun-21 Mar-21 Jun-20 Domestic Export 20 *FY21 Covid Impact
Slide 21: Financial Summary – Balance Sheet
Financial Summary – Balance Sheet Balance Sheet (INR Crs) FY17 FY18 FY19 FY20 FY21 Shareholder's Funds 188.7 215.7 474.3 813.5 1260.4 Debt 446.5 421.9 284.0 56.0 0.0 Other Long Term Liabilities 17.2 33.6 20.8 79.7 59.1 Other Current Liabilities 165.1 180.9 162.8 220.6 290.6 Equity & Liabilities 817.
Slide 22: Financial Summary – Statement of Profit and Loss
Financial Summary – Statement of Profit and Loss P&L (INR Crs) FY17 FY18 FY19 FY20 FY21 Q1FY22 Q4FY21 Q1FY21 Revenues 710.6 983.3 1,685.3 1,894.5 1,967.0 518.5 460.4 460.1 Other Income 1.3 6.3 10.4 16.0 24.3 5.7 6.2 5.8 Total Income 711.9 989.6 1,695.7 1,910.5 1,991.3 524.2 466.6 465.9 Gross Profits
Slide 23: Shareholder Information
Shareholder Information Stock Data (As on 30th June, 2021) Shareholding Pattern (%) Market Capitalization (₹) 3,569Crs 49.6% 51.2% 43.7% 43.7% Face Value(₹) 10 Share Price (₹) 608.1 EPS (₹) 11.4 52-Week High (₹) 898.4 6.7% 5.1% 52-Week Low (₹) 516.3 Promoter Institutional Others Symbol(NSE/BSE) IOLC
Slide 24: Thank You
Thank You For further details: Mr. Pardeep Kumar Khanna , CFO Email: pardeepkhanna@iolcp.com Phone: +91-161-2225531-35
IOL Chemicals and Pharmaceuticals — Investor Presentation (August 2021) on 6ix